If you're looking to bolster your portfolio with some blue chip shares, you may want to look at the two listed below.
Here's why these blue chip ASX 200 shares are highly rated right now:
CSL Limited (ASX: CSL)
The first ASX 200 blue chip share that could be in the buy zone is CSL. It is the biotherapeutics giant behind the CSL Behring business, which has developed a range of lifesaving and lucrative plasma therapies. In addition, the company has a growing Seqirus vaccine business and is on the brink of acquiring Vifor Pharma, which is focused on iron deficiency, nephrology and cardio-renal therapies.
The team at Morgans is positive on the company, particularly given the recovery in plasma collections. It recently put an add rating and $327.60 price target on its shares. Morgans commented:
"Promisingly, plasma collections continue to improve, although remain slightly below pre-pandemic levels, and while industry wide issues remain (eg Omicron; staffing; increase costs), the worst appears behind us."
"While near term challenges remain, the ongoing recovery in plasma collections, coupled with management's confidence, paints a favourable earnings picture."
Goodman Group (ASX: GMG)
Another ASX 200 blue chip share to consider is Goodman. It is an integrated property company with operations throughout Australia, New Zealand, Asia, Europe, the United Kingdom, North America and Brazil.
The company notes that its global property expertise, integrated own+develop+manage customer service offering and significant investment management platform ensures that it creates innovative property solutions that meet the individual requirements of its customers, such as Amazon, while seeking to deliver long-term returns for investors.
Citi is very positive on Goodman and currently has a buy rating and $29.50 price target on its shares. Its analysts believe Goodman could outperform its upgraded guidance in FY 2022. It commented:
"GMG's 1H22 EPS of 41.9c was 12% ahead of Visible Alpha consensus (37.3c) and 6% ahead of Citi (39.5c). FY22 EPS guidance was upgraded for the 2nd time in 6 months to 20% growth, or EPS of 78.7c, +1.5% ahead of ingoing consensus of 77.5c. FY22 DPS guidance was retained at 30c."
"We continue to see guidance as conservative, with our EPS estimates rising 5% in FY22 and c. 6% thereafter. We now forecast c. 23% EPS growth in FY22 and c. 19% EPS CAGR from FY21-FY24. Our TP increases 5% on higher asset values and higher earnings. GMG remains OUR top pick in the sector."
